India's first dengue vaccine approved India's drug regulatory authority has approved the Kydenga vaccine against dengue for use. The dengue vaccine has been approved in India. The vaccine named Kydenga, developed by a Japanese company against the dengue virus, has been approved for use in India. Developed by Japanese pharmaceutical company Takeda Pharmaceuticals , this vaccine has been approved by India's drug regulatory authority Central Drug Standards and Organization (CDACO). The Kydenga vaccine is said to provide protection against all four types of dengue virus serotypes 1, 2, 3 and 4 . Like the COVID-19 vaccine , it requires two doses. The second dose should be given three months after the first dose. This vaccine, which can be given to people aged 4 to 60 years, can also be given to those who have not had dengue. This vaccine, which is currently being produced in India, currently costs between Rs 6,000 and Rs 12,000 per dose . The price is expected to come down in ...
Microsoft AI chief warns: Studying consciousness in AI is ‘dangerous’ The rapid development of AI is generating both excitement and concern around the world. But a recent warning from Microsoft’s AI chief Mustafa Suleiman has given the debate a new twist. He said that researching AI consciousness could be dangerous. According to Suleiman, trying to give AI consciousness or studying it could lead to unnecessary controversy and risky applications. According to international media, Suleiman said that viewing AI as conscious could be dangerous. Doing so increases the possibility of showing AI as a living being or a being with rights. This could raise legal, ethical and policy questions. For example, if AI is considered conscious, the debate over whether it should be granted rights such as human rights arises. This could drag scientific research into philosophical debates and divert attention from actual technological development. He says that moving forward with AI in relation to cons...